Intercept Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	2017 - 2013
Net Income	-61.61	221.82	-91.43	-274.88	-344.68	-309.24	Upgrade
Depreciation & Amortization	0.61	2.26	7.53	8.21	9.05	4.58	Upgrade
Share-Based Compensation	24.01	21.89	28.03	49.19	55.98	49.91	Upgrade
Other Operating Activities	-26.03	-272.74	14.8	45.62	43.04	14.03	Upgrade
Operating Cash Flow	-63.02	-26.78	-41.07	-171.86	-236.61	-240.71	Upgrade
Capital Expenditures	0.19	-0.57	-0.4	-3.89	-1.14	-0.17	Upgrade
Change in Investments	167.08	-100.82	71.12	166.71	-187.85	-47.9	Upgrade
Other Investing Activities	-6.16	363.23	-	-	-	-	Upgrade
Investing Cash Flow	161.11	261.85	70.73	162.82	-188.99	-48.07	Upgrade
Share Issuance / Repurchase	1.33	1.68	-75.81	1.3	236.25	265.73	Upgrade
Debt Issued / Paid	-116.87	-268.44	116.79	0	223.42	0	Upgrade
Other Financing Activities	-0.43	-0.56	-39.87	-1.99	-2.16	-2.18	Upgrade
Financing Cash Flow	-115.97	-267.32	1.12	-0.69	457.52	263.55	Upgrade
Exchange Rate Effect	1.36	-6.3	-2.02	0.61	-0.39	-1.53	Upgrade
Net Cash Flow	-16.52	-38.55	28.76	-9.13	31.53	-26.77	Upgrade
Free Cash Flow	-62.83	-27.35	-41.46	-175.76	-237.75	-240.88	Upgrade
Free Cash Flow Margin	-19.78%	-9.57%	-15.90%	-75.12%	-94.34%	-133.97%	Upgrade
Free Cash Flow Per Share	-1.50	-0.81	-1.30	-5.33	-7.51	-8.46	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).